CordovaCann Corp
Change company Symbol lookup
Select an option...
LVRLF CordovaCann Corp
BTZ BlackRock Credit Allocation Income Trust
SLG SL Green Realty Corp
SKT Tanger Factory Outlet Centers Inc
SJR Shaw Communications Inc
SJM J M Smucker Co
SJI South Jersey Industries Inc
SHW Sherwin-Williams Co
SHV iShares Short Treasury Bond ETF
SH ProShares Short S&P500
Go


Based in Canada
Company profile

CordovaCann Corp. is a cannabis-focused consumer products company. The Company is focused on building a cannabis products business across multiple jurisdictions, including Canada and the United States. It provides services and investment capital to the processing and production vertical markets of the cannabis industry. It focuses to produce flower and extracts. The Company holds interest in 10062771 Manitoba Inc., a Manitoba-based cannabis retail venture. The Company operates recreational cannabis stores in Manitoba under the Star Buds brand.

Closing Price
$0.289
Day's Change
0.0593 (25.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.289
Day's Low
0.2283
Volume
(Heavy Day)
Volume:
241,701

10-day average volume:
126,753
241,701

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MESO, RTX and BIIB

9:26 pm ET November 18, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 18, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Mesoblast Limited (NASDAQ:MESO)

Investors Affected: April 16, 2019 - October 1, 2020

A class action has commenced on behalf of certain shareholders in Mesoblast Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/mesoblast-limited-loss-submission-form/?id=11055&from=1

Raytheon Technologies Corporation (NYSE:RTX)

Investors Affected: February 10, 2016 - October 27, 2020

A class action has commenced on behalf of certain shareholders in Raytheon Technologies Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and inadequate internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon Company's Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/raytheon-technologies-corporation-loss-submission-form/?id=11055&from=1

Biogen Inc. (NASDAQ:BIIB)

Investors Affected: October 22, 2019 - November 6, 2019

A class action has commenced on behalf of certain shareholders in Biogen Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/biogen-inc-loss-submission-form/?id=11055&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (212) 537-9430Fax: (833) 862-7770SOURCE: The Gross Law Firm

View source version on accesswire.com: https://www.accesswire.com/617488/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-MESO-RTX-and-BIIB

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.